Status:
COMPLETED
Added Value of Contrast Enhanced Spectral Mammography, CESM. A Pilot Study.
Lead Sponsor:
Region Skane
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Introduction: To avoid unnecessary mastectomies and reoperations a correct size assessment of malignant lesions in breast is required. Sometimes a supplementary MRI is therefore recommended. However, ...
Eligibility Criteria
Inclusion
- Patients diagnosed with breast cancer and whom are planned for primary surgery
- Signed informed consent
Exclusion
- Ongoing pregnancy
- Ongoing lactation
- Allergy against iodine contrast
- Treatment with metformin (against diabetes)
- Renal failure
- Hyperthyroidism
- Severe heart condition
- Myasthenia gravis
- Implants
- Inability to understand study information
Key Trial Info
Start Date :
November 28 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 19 2018
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT03402529
Start Date
November 28 2017
End Date
October 19 2018
Last Update
January 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Surgery
Lund, Sweden, 221 85